Pretreatment transcriptional profiling for predicting response to neoadjuvant chemoradiotherapy in rectal adenocarcinoma

Clinical Cancer Research

Volumn 17, Issue 9, 2011, Pages 3039-3047

  Brettingham Moore, Kate H ^a   Duong, Cuong P ^a,c   Greenawalt, Danielle M ^a   Heriot, Alexander G ^a,c   Ellul, Jason ^a   Dow, Christopher A ^d   Murray, William K ^a   Hicks, Rodney J ^a   Tjandra, Joe ^e   Chao, Michael ^b   Bui, Andrew ^f   Joon, Daryl Lim ^g   Thomas, Robert J S ^a,c   Phillips, Wayne A ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b Radiation Oncology Victoria   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d WESTERN HOSPITAL   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f Department of Surgery ^*  (Australia)

^g AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLASSIFIER; COHORT ANALYSIS; COMPUTER PREDICTION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; LEARNING ALGORITHM; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PREOPERATIVE CARE; PRIORITY JOURNAL; RECTUM CARCINOMA; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR BIOPSY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; COMBINED MODALITY THERAPY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; RECTAL NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 79955505095     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2915     Document Type: Article

References (49)

1. Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009;27:5124-30.
2. Ciccocioppo A, Stephens JH, Hewett PJ, Rieger NA. Complete pathologic response after preoperative rectal cancer chemoradiotherapy. ANZ J Surg 2009;79:481-4.
3. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23:8688-96. (Pubitemid 46211512)
4. Hiotis SP, Weber SM, Cohen AM, Minsky BD, Paty PB, Guillem JG, et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg 2002;194:131-5; discussion 135-6.
5. Rosenthal DI, Catalano PJ, Haller DG, Landry JC, Sigurdson ER, Spitz FR, et al. Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297. Int J Radiat Oncol Biol Phys 2008;72:108-13.
6. Baynes RD, Gansert J. KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer. Am J Ther 2009;16:554-61.
7. Fakih MM. KRAS mutation screening in colorectal cancer: from paper to practice. Clin Colorectal Cancer 2010;9:22-30.
8. Lin AY, Wong WD, Shia J, Minsky BD, Temple LK, Guillem JG, et al. Predictive clinicopathologic factors for limited response of T3 rectal cancer to combined modality therapy. Int J Colorectal Dis 2008;23:243-9.
9. Lin LC, Lee HH, Hwang WS, Li CF, Huang CT, Que J, et al. p53 and p27 as predictors of clinical outcome for rectal-cancer patients receiving neoadjuvant therapy. Surg Oncol 2006;15:211-6. (Pubitemid 46771194)
10. Gosens MJ, Moerland E, Lemmens VP, Rutten HT, Tan-Go I, Van Den Brule AJ. Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer. Int J Cancer 2008;123:1941-9.
11. Marcuello E, Altes A, del Rio E, Cesar A, Menoyo A, Baiget M. Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracilbased chemotherapy in advanced colorectal cancer patients. Int J Cancer 2004;112:733-7. (Pubitemid 39435256)
12. Qiu LX, Tang QY, Bai JL, Qian XP, Li RT, Liu BR, et al. Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies. Int J Cancer 2008;123:2384-9.
13. Belvedere O, Puglisi F, Di Loreto C, Cataldi P, Guglielmi A, Aschele C, et al. Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5- fluorouracil in advanced colorectal cancer. Ann Oncol 2004;15:55-8. (Pubitemid 38139604)
14. Findlay MP, Cunningham D, Morgan G, Clinton S, Hardcastle A, Aherne GW. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 1997;75:903-9. (Pubitemid 27110709)
15. Saw RP, Morgan M, Koorey D, Painter D, Findlay M, Stevens G, et al. p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Dis Colon Rectum 2003;46:192-202.
16. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
17. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26. (Pubitemid 40051905)
18. Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005;23:1826-38. (Pubitemid 46217459)
19. Kim IJ, Lim SB, Kang HC, Chang HJ, Ahn SA, Park HW, et al. Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum 2007;50:1342-53. (Pubitemid 47472394)
20. Rimkus C, Friederichs J, Boulesteix AL, Theisen J, Mages J, Becker K, et al. Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clin Gastroenterol Hepatol 2008;6:53-61. (Pubitemid 350309530)
21. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994;73:2680-6. (Pubitemid 24166250)
22. Bouzourene H, Bosman FT, Seelentag W, Matter M, Coucke P. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 2002;94:1121-30. (Pubitemid 34150868)
23. Gautier L, Cope L, Bolstad BM, Irizarry RA. Affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004;20:307-15. (Pubitemid 38262761)
24. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
25. Team RDC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2009.
26. Bolstad BM. Low Level Analysis of High-density Oligonucleotide Array Data: Background, Normalization and Summarization. Berkeley, CA: University of California Berkeley; 2004.
27. Brettschneider J, Collin F, Bolstad BM, Speed TP. Quality assessment for short oligonucleotide arrays. Technometrics 2008;50:241-64.
28. Bolstad B, Collin F, Brettschneider J, Simpson K, Cope L, Irizarry R, , et al. Quality Assessment of Affymetrix GeneChip Data in Bioinformatics and Computational Biology Solutions Using R and Bioconductor. New York: Springer; 2005.
29. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
30. Smyth GK. Limma: Linear Models for Microarray Data. New York: Springer; 2005. p. 397-420.
31. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B1995;57:289-300.
32. Dimitiadou E, Hornik K, Friedrich L, Meyer D, Weingessel A. e1071: Misc Functions of the Department of Statistics (e1071), TU Wien. R package version; Wien, Austria: Technische Universität Wien; 2010 p. 1.5-2.4.
33. Dettling M, Maechler M. Supclust: Supervised Clustering of Genes. R package version. Wien, Austria: Technische Universität Wien; 2005. p. 1.0-5.1.
34. Barrier A, Boelle PY, Lemoine A, Tse C, Brault D, Chiappini F, et al. Gene expression profiling of nonneoplastic mucosa may predict clinical outcome of colon cancer patients. Dis Colon Rectum 2005;48:2238-48. (Pubitemid 43074444)
35. Barrier A, Roser F, Boelle PY, Franc B, Tse C, Brault D, et al. Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene 2007;26:2642-8. (Pubitemid 46632008)
36. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997;12:19-23. (Pubitemid 27138353)
37. Gavioli M, Bagni A, Piccagli I, Fundaro S, Natalini G. Usefulness of endorectal ultrasound after preoperative radiotherapy in rectal cancer: comparison between sonographic and histopathologic changes. Dis Colon Rectum 2000;43:1075-83. (Pubitemid 30626139)
38. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521-30. (Pubitemid 37151509)
39. Lee SH, Ryu JK, Lee KY, Woo SM, Park JK, Yoo JW, et al. Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett 2008;259:39-49. (Pubitemid 350235089)
40. Morris M, Platell C, Iacopetta B. Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res 2008;14:1413-7. (Pubitemid 351413923)
41. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-92. (Pubitemid 44390989)
42. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009. (Pubitemid 35461656)
43. Reid JF, Lusa L, De Cecco L, Coradini D, Veneroni S, Daidone MG, et al. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst 2005;97:927-30. (Pubitemid 41417944)
44. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005;365:488-92.
45. Berg AO, Armstrong K, Botkin J, Calonge N, Haddow J, Hayes M, et al. Recommendations from the EGAPP working group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med 2009;11:66-73.
46. Duong C, Greenawalt DM, Kowalczyk A, Ciavarella ML, Raskutti G, Murray WK, et al. Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer. Ann Surg Oncol 2007;14:3602-9. (Pubitemid 350160118)
47. Maher SG, Gillham CM, Duggan SP, Smyth PC, Miller N, Muldoon C, et al. Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann Surg 2009;250:729-37.
48. Schauer M, Janssen KP, Rimkus C, Raggi M, Feith M, Friess H, et al. Microarray-based response prediction in esophageal adenocarcinoma. Clin Cancer Res 2010;16:330-7.
49. Brettingham-Moore KH, Duong CP, Heriot AG, Thomas RJ, Phillips WA. Using gene expression profiling to predict response and prognosis in gastrointestinal cancers-the promise and the perils. Ann Surg Onc 2011; In press.